ASX Announcement Racura Successfully Demonstrates Pharmacokinetic Equivalence of RC110 & RC220 § A nonclinical pharmacokinetic bridging study has found that RC220 and the earlier RC110 formulation of (E,E)-bisantrene deliver equivalent systemic drug exposure § Ratios of peak and total drug...
Racura Successfully PK Bridges RC110 RC220
Filed with ASX · · 5 pages · English
Release
In the deck
Earlier from Racura Oncology
- Racura Presents Bisantrene MYC Data at FCS 2026
- Letter to Shareholders, Notice of AGM & Proxy Form
- Sept 2026 Quarterly Activities Report and Appendix 4C
- HARNESS-1 First Cohort Cleared
- Racura Presents CPACS Data at GCOS 2026
Later from Racura Oncology
All Racura Oncology news releasesFollow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology